It is surprising that, so far as we can ascertain, no trial has been reported in which the efficacy of a modern " antidepressive " drug has been compared with that of a combination of drugs (dexamphetamine and amylobarbitone) widely used in the treatment of depressive illness before the newer drugs were introduced five or six years ago. Proprietary mixtures of dexamphetamine and amylobarbitone are still advertised as of value in depression, and the lack of any comparative trial is perhaps more surprising when it is remembered that the basic cost to the National Health Service of a week's treatment with the ingredients of such mixtures (dexamphetamine sulphate 5 mg. and amylobarbitone sodium 50 mg. t.i.d.) is 5d., while that of the currently most popular antidepressant (imipramine hydrochloride (" tofranil ") 
Assessment and Analysis
The clinical state of subjects was assessed at entry to the trial and at the end of each three-weeks period. Aspects of the clinical state were rated on a five-point scale (absent, mild, moderate, marked, severe). These aspects were: depression, agitation, anxiety, retardation, hypochondria, paranoid attitude, insomnia, and overall clinical state. The observations on which the assessments of depression, agitation, and anxiety were based have been described (Hare et al., 1962) . Hypochondria was assessed in terms of a morbid belief in the presence of physical disease or undue preoccupation with physical symptoms and the possibility of disease. Insomnia was rated solely on the subject's statement, no account being taken of whether or not he was receiving hypnotics. In addition, the subject's weight was recorded at the time of the assessment.
Each assessment was based on a clinical interview conducted mainly by the first assessor, at which the second assessor and others present were free to ask the patient questions. Each assessor recorded his ratings before there was any discussion of the case. Assessors have been classed as " first " and " second." The first assessors were those with longest experience in clinical psychiatry; the second assessors were, so far as was possible, the registrars concerned with the day-to-day management of the case. For 69 of the 78 subjects completing the six-weeks trial, the first assessor was the consultant in charge of the case (E. H. H. or C. McC.). A second observer was present for 70 subjects, and in 62 of these he was the registrar concerned with the case. Altogether there were 18 second assessors.
The assessments provided data for a self-controlled series which was analysed by the sequential method (Armitage, 1960) . A subject's ratings at the end of the first period were compared with those of the second period and the results expressed in terms of the severity of a clinical manifestation in one period being " better than," " equal to," or " worse than " that in the other period. Also, where there was a change in weight of more than 2 lb. (0.9 kg.), the period with the greater weight was considered "better than" the other period as regards weight increase. These comparisons were then assumed to represent the comparative clinical effect of the drugs given during the periods.
Results
Figs. 1 and 2 show the results for the first assessors. The sequential charts (Armitage, 1960) 
Discussion
One clear-cut conclusion emerges from this trial: under the conditions of the trial and for the dosages given, the effect of imipramine on the clinical manifestation of depression in depressive illness is no different from that of drinamyl. Drinamyl is a mixture of dexamphetamine and amylobarbitone. We can find only two reports of controlled trials (Doust et al., 1959; Hare et al., 1962) in which dexamphetamine has been compared with a placebo in the treatment of depressive illness, and in both of these dexamphetamine was found no better than the placebo; these results are supported by the controlled study of Legge and Steinberg (1962) . Thus our conclusion from the present trial is that imipramine has no specific antidepressive action.
It is less clear-cut from this trial whether imipramine has any general advantage over drinamyl in the treatment of depressive illness.
On the whole, however, we incline to give greater weight to the first assessors' comparisons, and so to conclude that imipramine was probably superior to drinamyl in relieving agitation and in increasing weight. It cannot be decided whether these effects were due to imipramine causing an improvement or to drinamyl causing a worsening, but it seems more reasonable to adopt the former view, at least with regard to agitation.
In a previous paper (Hare et al., 1962) it was found that phenelzine in depressive illness was superior to a placebo only in its effects on agitation and anxiety. The results of that trial and of the present one may therefore be taken to support the view that, in so far as antidepressive drugs are effective in the treatment of depressive illness, this is in virtue of a sedative action. Other evidence may be cited in support of this. Imipramine and " Drnamyl "-Hare et al. BRfTM Rees et al. (1961) , comparing imipramine with a placebo, found that the beneficial effect of imipramine was greater on the symptom of anxiety than on that of depression. Roulet et al. (1962) , while finding no significant difference in the clinical effects of imipramine and a placebo, noted that patients showed less anxiety on psychological testing when receiving the imipramine. The clinical experience of Sargant and Dally (1962) , which led them to conclude that antidepressive drugs were effective in some states of anxiety as well as in depressive illness, is also understandable in terms of a purely sedative action of the drugs. It may be noted, too, that drowsiness is an accepted side-effect of at least three antidepressive drugs (phenelzine, tranylcypromine, and amitriptyline).
In the present trial we administered the drugs for periods of three weeks each. We did this in deference to a widely held view that the antidepressive effects of imipramine (and of most other antidepressive drugs but not, curiously enough, of dexamphetamine) do not become apparent until the second or third week of treatment. If (as our results suggest) imipramine has no specifically antidepressive action, then, of course, the problem of delayed action does not arise. But, in any case, it would be a matter of great difficulty to establish that the antidepressant effects of a drug do not become apparent for several weeks. It would be necessary to show by a controlled trial, firstly, that there was no difference between the effects of a drug and of a placebo during the first week or two, and, secondly, that thereafter the effect of the drug became significantly better. This has never been done, and the evidence for the delayed-action hypothesis has been derived entirely (so far as we can determine) from uncontrolled observations. Yet the high rate of natural remission in depressive illness must make such uncontrolled observations a hazardous means of arriving at the truth.
The question whether modem antidepressive drugs are of value is still undecided. We have been able to find, in British and American journals, reports of 10 controlled trials in which imipramine was compared with a placebo in the treatment of depressive illness: in four of these (Ball and Kiloh, 1959 ; Rees et al., 1961 ; Friedman et al., 1961 ; Abraham et al., 1963) imipramine was found to be significantly better than a placebo; in five (Doust et al., 1959; H6hn et al., 1961 ; Ashby and Collins, 1961 ; Overall, 1961 ; Roulet et al., 1962) 
